- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03444103
A Pilot Trial of Clazakizumab in Late ABMR
Safety, Tolerability and Efficacy of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection After Kidney Transplantation - a Pilot Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Part A:
Patients positive for anti-HLA donor-specific antibodies (DSA) and with biopsy-proven late ABMR (Acute/active or chronic/active phenotype according to the Banff 2015 classification) will be identified and recruited at the kidney transplantation outpatient services of the two center sites. Participants will be randomized to receive either clazakizumab or placebo subcutaneously (1:1 randomization stratified for ABMR type) for a period of 12 weeks (administration of clazakizumab/placebo at day 0, and after 4 and 8 weeks). After 12 weeks, patients will be subjected to a first follow-up biopsy. Primary goals of this part of the trial are to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a short course of treatment. Moreover, part A will allow for a first preliminary assessment of the impact of clazakizumab on ABMR-associated inflammation detected in peripheral blood and in the rejecting organ allograft, on the pharmacokinetics of pantoprazole as a probe drug to investigate influence of IL-6 blockade on cytochrome P450 (CYP) dependent drug metabolism (potential effects on the half-life of CYP-metabolized drugs such as pantoprazole, and on the short-term course of DSA mean fluorescence intensity (MFI) and kidney allograft function (eGFR, urinary protein excretion). The randomization sequence will be unblinded for a first data analysis after the last patient has completed the 12-week follow-up period.
Part B:
After completion of part A after 12 weeks, all study patients will enter part B, an open-label part of the study. All 20 subjects will receive subcutaneous clazakizumab in 4-weekly intervals until the end-of-study (EOS) visit after 52 weeks and will then be subjected to a second protocol biopsy. Major goals of part B are to evaluate the safety and tolerability of a prolonged period of treatment with clazakizumab and the long-term impact of this antibody on the evolution of ABMR, rejection-associated biomarkers and kidney allograft function and survival over a period of 12 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Voluntary written informed consent
- Age >18 years
- Functioning living or deceased donor allograft after ≥365 days post-transplantation
- eGFR >30 ml/min/1.73 m2
- Detection of HLA class I and/or II antigen-specific antibodies (preformed and/or de novo DSA).
- Acute/active or chronic/active ABMR (±C4d in PTC) according to Banff 2013/2015
- Molecular ABMR score (ABMRpm) ≥0.2
Exclusion Criteria:
- Patients actively participating in another clinical trial
- Age ≤18 years
- Female subject is pregnant or lactating
- Index biopsy results:
- T-cell-mediated rejection classified Banff grade ≥I
- De novo or recurrent severe thrombotic microangiopathy
- Polyoma virus nephropathy
- De novo or recurrent glomerulonephritis
- Acute rejection treatment <3 month before screening
- Acute deterioration of graft function (eGFR decline within 1-3 months >25%)
- Nephrotic range proteinuria >3500 mg/g protein/creatinine ratio
- Active viral, bacterial or fungal infection precluding intensified immunosuppression
- Active malignant disease precluding intensified immunosuppressive therapy
- Abnormal liver function tests (ALT, AST, bilirubin > 1.5 x upper limit of normal)
- Other significant liver disease
- Latent or active tuberculosis (positive QuantiFERON-TB-Gold test, Chest X-ray)
- Administration of a live vaccine within 6 weeks of screening
- Neutropenia (<1 G/L) or thrombocytopenia (<100 G/L)
- History of gastrointestinal perforation, diverticulitis, or inflammatory bowel disease
- Allergy against proton pump inhibitors
- History of alcohol or illicit substance abuse
- Serious medical or psychiatric illness likely to interfere with participation in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Clazakizumab / Clazakizumab
Monthly subcutaneous injections of 25mg clazakizumab for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).
|
Humanized monoclonal anti-IL-6 antibody
Other Names:
|
PLACEBO_COMPARATOR: Placebo / Clazakizumab
Monthly subcutaneous injections of placebo (saline) for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).
|
0.9% Saline
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events and severe adverse events (AE's, SAE's)
Time Frame: 12 months
|
Serious and Non-Serious adverse events probably or possibly attributable to clazakizumab
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-clazakizumab antibodies in serum
Time Frame: At 0, 12 and 52 weeks
|
- Concentration of anti-clazakizumab antibodies in serum (ng/mL)
|
At 0, 12 and 52 weeks
|
Clazakizumab serum concentration
Time Frame: At 0, 12 and 52 weeks
|
- Total clazakizumab serum concentration (ng/mL)
|
At 0, 12 and 52 weeks
|
Pantoprazole serum concentration
Time Frame: At 0, 12 and 52 weeks
|
- Effect of clazakizumab on pantoprazole serum concentration (nanogram per mL)
|
At 0, 12 and 52 weeks
|
Protocol biopsy results - microcirculation inflammation
Time Frame: At week 11 and at week 52
|
- Microcirculation inflammation (g+ptc score), scale 0-3, higher = worse prognosis
|
At week 11 and at week 52
|
Protocol biopsy results - chronic damage
Time Frame: At week 11 and at week 52
|
- Transplant glomerulopathy (cg) and interstitial fibrosis/tubular atrophy (IFTA) scores, scale 0-3, higher = worse prognosis
|
At week 11 and at week 52
|
Protocol biopsy results - molecular signs of ABMR
Time Frame: At week 11 and at week 52
|
- Molecular ABMR score (molecular microscope, MMDx), scale 0-1 in 0.1 steps, higher = worse prognosis
|
At week 11 and at week 52
|
Protocol biopsy results - ABMR phenotype
Time Frame: At week 11 and at week 52
|
- Archetype analysis of gene expression profiles (molecular microscope, MMDx), ABMR archetype score, scale 0-1 in 0.1 steps, higher = worse prognosis
|
At week 11 and at week 52
|
Anti-HLA antibody levels - antibody strength
Time Frame: At 0, 12 and 52 weeks
|
- Maximum and sum of mean fluorescence intensity (MFI) of DSA (Luminex) - higher is worse
|
At 0, 12 and 52 weeks
|
Anti-HLA antibody levels - number of DSA
Time Frame: At 0, 12 and 52 weeks
|
- Number of DSA (Luminex) - more is worse
|
At 0, 12 and 52 weeks
|
Anti-HLA antibody levels - broadness of antibody reactivity
Time Frame: At 0, 12 and 52 weeks
|
- Broadness of sensitization (virtual PRA, Luminex), scale: %, higher = worse
|
At 0, 12 and 52 weeks
|
Allograft function - eGFR
Time Frame: At day 0, week 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 51 and 52
|
- Estimated GFR (CKD-EPI, mL/min/1.73m2)
|
At day 0, week 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 51 and 52
|
Allograft function - protein excretion in spot urine
Time Frame: At day 0, week 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 51 and 52
|
- Urinary protein excretion in spot urine (protein/creatinine ratio in mg/g)
|
At day 0, week 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 51 and 52
|
Total IgG concentration
Time Frame: At 0, 12 and 52 weeks
|
- Nephelometry, mg/dL
|
At 0, 12 and 52 weeks
|
Total IgM concentration
Time Frame: At 0, 12 and 52 weeks
|
- Nephelometry, mg/dL
|
At 0, 12 and 52 weeks
|
Total IgA concentration
Time Frame: At 0, 12 and 52 weeks
|
- Nephelometry, mg/dL
|
At 0, 12 and 52 weeks
|
IgG subclass 1 (IgG1)
Time Frame: At 0, 12 and 52 weeks
|
- ELISA, mg/dL
|
At 0, 12 and 52 weeks
|
IgG subclass 2 (IgG2)
Time Frame: At 0, 12 and 52 weeks
|
- ELISA, mg/dL
|
At 0, 12 and 52 weeks
|
IgG subclass 3 (IgG3)
Time Frame: At 0, 12 and 52 weeks
|
- ELISA, mg/dL
|
At 0, 12 and 52 weeks
|
IgG subclass 4 (IgG4)
Time Frame: At 0, 12 and 52 weeks
|
- ELISA, mg/dL
|
At 0, 12 and 52 weeks
|
Effect on leukocyte subsets in peripheral blood
Time Frame: At 0, 12 and 52 weeks
|
- Fluorescence intensity (0 to no upper limit)
|
At 0, 12 and 52 weeks
|
Cytokine patterns and endothelial activation/injury markers in serum
Time Frame: At 0, 12 and 52 weeks
|
- Luminex bead panels, mean fluorescence intensities (MFI)
|
At 0, 12 and 52 weeks
|
Effect on IL-6 gene expression in peripheral blood cells
Time Frame: At 0, 12 and 52 weeks
|
rtPCR
|
At 0, 12 and 52 weeks
|
Effect on IL-6R gene expression in peripheral blood cells
Time Frame: At 0, 12 and 52 weeks
|
rtPCR
|
At 0, 12 and 52 weeks
|
Patient survival
Time Frame: 12 months
|
Death: number of events, time to event
|
12 months
|
Graft survival
Time Frame: 12 months
|
Graft loss: number of events, time to event
|
12 months
|
Occurrence of biopsy-proven acute rejection necessitating rejection treatment
Time Frame: At week 52
|
Number of anti-rejection treatments with a substance other than the study drug
|
At week 52
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bernd Jilma, MD, Department of Clinical Pharmacology, Medical University Vienna
Publications and helpful links
General Publications
- Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Arthritis Rheumatol. 2016 Sep;68(9):2163-73. doi: 10.1002/art.39700.
- Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, Kim I, Louie S, Kang A, Peng A, Kahwaji J, Reinsmoen N, Toyoda M, Jordan SC. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. Am J Transplant. 2017 Sep;17(9):2381-2389. doi: 10.1111/ajt.14228. Epub 2017 Mar 10.
- Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, Hidalgo LG, Haslacher H, Kaltenecker CC, Aretin MB, Oberbauer R, Posch M, Staudenherz A, Handisurya A, Reeve J, Halloran PF, Bohmig GA. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol. 2018 Feb;29(2):591-605. doi: 10.1681/ASN.2017070818. Epub 2017 Dec 14.
- Mayer KA, Doberer K, Halloran PF, Budde K, Haindl S, Muhlbacher J, Eskandary F, Viard T, Casas S, Jilma B, Bohmig GA. Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10. Transplant Direct. 2022 Nov 10;8(12):e1406. doi: 10.1097/TXD.0000000000001406. eCollection 2022 Dec.
- Muhlbacher J, Schorgenhofer C, Doberer K, Durr M, Budde K, Eskandary F, Mayer KA, Schranz S, Ely S, Reiter B, Chong E, Adler SH, Jilma B, Bohmig GA. Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism. Transpl Int. 2021 Aug;34(8):1542-1552. doi: 10.1111/tri.13954. Epub 2021 Jul 8.
- Eskandary F, Durr M, Budde K, Doberer K, Reindl-Schwaighofer R, Waiser J, Wahrmann M, Regele H, Spittler A, Lachmann N, Firbas C, Muhlbacher J, Bond G, Halloran PF, Chong E, Jilma B, Bohmig GA. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials. 2019 Jan 11;20(1):37. doi: 10.1186/s13063-018-3158-6.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- EK1428/2017
- 2017-001604-30 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antibody-mediated Rejection
-
Brigham and Women's HospitalAlexion PharmaceuticalsTerminatedAntibody-mediated Rejection | Humoral RejectionUnited States
-
Shahid Beheshti University of Medical SciencesRecruitingAntibody-mediated RejectionIran, Islamic Republic of
-
Medical University of ViennaRecruitingLung Transplant Rejection | Antibody-mediated RejectionAustria
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruitingAntibody-mediated RejectionChina
-
Farsad EskandaryCharite University, Berlin, Germany; University of Alberta; HI-BioCompleted
-
CSL BehringTerminatedAntibody-mediated RejectionUnited States, Spain, France, Netherlands, United Kingdom, Belgium, Germany
-
University of ManitobaTerminatedAntibody Mediated RejectionCanada
-
Thomas MuellerUnknownAntibody-mediated Rejection
-
Duke UniversityBristol-Myers SquibbWithdrawnLung Transplant Rejection | Antibody-mediated Rejection
-
University Hospital, MontpellierInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedAntibody-mediated RejectionFrance
Clinical Trials on Clazakizumab / Clazakizumab
-
Cedars-Sinai Medical CenterCompleted
-
NYU Langone HealthCompleted
-
Columbia UniversityNYU Langone Health; CSL BehringTerminated
-
Anne B. NewmanCSL BehringRecruitingImproving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study (RIGHT)Inflammation | FrailtyUnited States
-
The Methodist Hospital Research InstituteUnknown
-
Stanley Jordan, MDActive, not recruitingKidney Transplant Rejection | Kidney Transplant; Complications | Antibody-mediated Rejection | Transplant Glomerulopathy | Transplant Glomerulopathy - Late Form | Transplant Glomerulopathy - Early FormUnited States
-
CSL BehringCompletedRheumatoid ArthritisItaly, United States, France, Argentina, Mexico, Japan, Canada, Hungary, South Africa
-
CSL BehringActive, not recruitingEnd Stage Kidney Disease | Atherosclerotic Cardiovascular DiseaseUnited States, Australia, Belgium, Canada, Germany
-
Stanley Jordan, MDActive, not recruitingKidney Failure, Chronic | End-Stage Renal Disease | Kidney Transplant; Complications | Antibody-mediated Rejection | Kidney Transplant Failure and Rejection | Transplant;Failure,Kidney | Transplant GlomerulopathyUnited States
-
CSL BehringTerminatedCrohn's DiseaseGermany, India, Korea, Republic of, Taiwan, United States, Hong Kong, Canada, Mexico, Austria, Switzerland, Israel, Italy, France, Poland, Netherlands, Hungary, Czechia, United Kingdom